Literature DB >> 3537345

On lymphokines, cytokines, and breakthroughs.

C G Moertel.   

Abstract

Mesh：

Substances：

Year:  1986        PMID： 3537345

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  5 in total

1.  To the editor.

Authors:  J R Yannelli; A M Bastin; M Jadus
Journal:  Cytotechnology       Date:  1988-02       Impact factor: 2.058

Review 2.  Interleukin 2.

Authors:  T J Hamblin
Journal:  BMJ       Date:  1990-02-03

3.  Serum levels of the low-affinity interleukin-2 receptor molecule (TAC) during IL-2 therapy reflect systemic lymphoid mass activation.

Authors:  S D Voss; J A Hank; C A Nobis; P Fisch; J A Sosman; P M Sondel
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

Review 4.  The clinical potential of interleukin-2.

Authors:  R T Oliver
Journal:  Br J Cancer       Date:  1988-10       Impact factor: 7.640

5.  Patients with metastatic renal carcinoma candidate for immunotherapy with cytokines. Analysis of a single institution study on 181 patients.

Authors:  T Philip; S Negrier; C Lasset; B Coronel; M Bret; J Y Blay; Y Merrouche; C Carrie; P Kaemmerlen; F Chauvin
Journal:  Br J Cancer       Date:  1993-11       Impact factor: 7.640
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.